TickerTalks
Browse all tickers →
TickerTalks›$BOLD
BOBOLD

Boundless Bio, Inc.

$BOLD·$65M·Biotechnology·Healthcare
$2.83+2.0%YTD+121.7%1Y+141.9%
Mentions · last 7 days
2026-08-07: 2 posts2026-08-08: 1 posts2026-08-09: 3 posts2026-08-10: 3 posts2026-08-11: 9 posts2026-08-12: 6 posts2026-08-13: 3 posts28+14%
Price updated 23h ago·X counts updated 2d ago
BOBOLD
$BOLDBoundless Bio, Inc.
$2.83+1.98%28 posts+14%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $BOLD, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-08-14

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Pre-revenue oncology biotech in an active M&A situation — shareholder-rights investigations are the flashing sign, Kevin Tang has been buying, and X is talking about a different BOLD.

Boundless Bio has zero revenue across the last four quarters with EPS -$0.58 to -$0.70, so this isn't a fundamentals story — Halper Sadeh and Monteverde & Associates are actively investigating whether the board is obtaining a fair price for shareholders, which reads as an M&A takeout process at a contested valuation.

  • Kevin Tang made five open-market buys around $2.44 — Tang Capital is a well-known biotech activist/liquidation investor, and cluster buying at these prices signals a view that the takeout price should be higher than what's implied.
  • +148% over 12 months, +122% YTD, position 91% of 52-week range and +84% above 200-day MA — the tape has already re-rated on the M&A speculation; new money is buying deal-arb outcome, not the pipeline.
  • Analyst coverage is 1 EPS analyst modeling losses through 2027; revenue only appears in FY28 estimates at $8.4M — the standalone case is genuinely long-dated, which is why the M&A is the whole story.

Next print 2026-11-05 is scheduled but the real event is a definitive deal announcement, a competing bidder, or a formal rejection of the current offer.

Differs from X sentimentThe X sentiment for '$BOLD' is entirely about the Liquity Protocol Ethereum-dollar stablecoin, not Boundless Bio — a common ticker/token collision. That crowd view has no bearing on this equity and should not be used to gauge sentiment on the biotech.

What to watch: Any 8-K disclosing a definitive M&A agreement, a competing bid, revised offer price, or Tang Capital 13D filing — plus the November 5 update as a formal cadence marker.

On the calendar: 2026-11-05 — quarterly update (real event: any M&A definitive)

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-08-13

The $BOLD conversation is small and entirely about the Liquity Protocol Ethereum-dollar stablecoin. Bulls point to Tether buying gold as validation that decentralized/immutable stablecoins deserve share, ~10% ETH yield paid in ETH via the Liquity Carry Vault on Fusion/IPOR, and $BOLD growth as a decentralized alternative to centralized issuers. No bearish voice.

Read the AI verdict + X sentiment for $BOLD

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage oncology company targeting extrachromosomal DNA with CHK1 inhibitor BBI-355 for oncogene-amplified cancers.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $BOLD.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $BOLD

Partial — Clinical-stage oncology company targeting extrachromosomal DNA with CHK1 inhibitor BBI-355 for oncogene-amplified cancers; partial earnings exposure to biotechnology demand dynamics through its product portfolio.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+44.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-45.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-81.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-53.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.6Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-1.06$-1.060.0%
Q1 2026May 8, 2026$-0.60$-0.51-17.6%
Q4 2025Mar 9, 2026$-0.58$-0.44-31.8%
Q3 2025Nov 5, 2025$-0.62$-0.53-17.0%
Next earningsThu, Nov 5·consensus EPS $-0.56

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.60$-15.0M
Q4 FY25$0———$-0.58$-10.5M
Q3 FY25$0———$-0.62$-10.2M
Q2 FY25$0———$-0.70$-11.9M

Forward consensus

5-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$2.40-$2.40 – -$2.400
FY27$0$0 – $0-$0.93-$0.93 – -$0.930
FY28$8.4M$8.4M – $8.4M-$1.56-$1.56 – -$1.561
FY29$0$0 – $0-$1.34-$1.34 – -$1.340
FY30$0$0 – $0-$1.40-$1.40 – -$1.400

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.93%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+23.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+86.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 17.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.385-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyJul 21Kevin Tang10% owner3.0K sh$7KBuyJul 20Kevin Tang10% owner1.6K sh$4KBuyJul 17Kevin Tang10% owner265 sh$647BuyJul 16Kevin Tang10% owner18.5K sh$45KBuyJul 15Kevin Tang10% owner1.6K sh$4KBuyJul 14Kevin Tang10% owner43.9K sh$107KBuyJul 13Kevin Tang10% owner48.2K sh$117KBuyJul 10Kevin Tang10% owner43.4K sh$105KBuyJul 9Kevin Tang10% owner7 sh$17BuyJul 8Kevin Tang10% owner14.3K sh$35K
1–10 of 20
+ 6 other (4 awards · 2 exempts) in window

See when $BOLD insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJun 293
AI summary

Kevin Tang (Tang Capital Management) holds 2,247,512 shares of Boundless Bio as a 10%+ beneficial owner as of June 25, 2026. Tang Capital is a well-known biotech activist and investor; their position disclosure in this oncology company signals potential engagement and adds a high-profile investor to the shareholder register.

8-KMaterial agreementJun 238-K — Item 1.01: Material agreement · Item 2.05: Restructuring / exit costs · Item 3.02: Unregistered equity sale · Item 5.01: Change in control · Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Delaware 001-41989 83-0751369 entered into a material merger agreement on 2026-06-23 for $0.0001. Narrative: erger Agreement On June 22, 2026, Boundless Bio, Inc., a Delaware corporation (Boundless Bio), entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement) with Serapha Bio, Inc., a Delaware corporation (Serapha), and Boulder Merger Sub Corp., a Delaware corporation and who... Delaware 001-41989 83-0751369 reported a compensatory arrangement or officer/director change: erger Agreement On June 22, 2026, Boundless Bio, Inc., a Delaware corporation (Boundless Bio), entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement) with Serapha Bio, Inc., a Delaware corporation (Serapha), and Boulder Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of Boundless Bio (Merger Sub). Upon the terms and subject to the satisfaction o. Delaware 001-41989 83-0751369 disclosed: erger Agreement On June 22, 2026, Boundless Bio, Inc., a Delaware corporation (Boundless Bio), entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement) with Serapha Bio, Inc., a Delaware corporation (Serapha), and Boulder Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of Boundless Bio (Merger Sub). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, Merger Sub will be merged with and into Serapha,.

8-KShareholder voteJun 178-K — Item 5.07: Shareholder vote
AI summary

Delaware 001-41989 83-0751369 disclosed voting results from its annual or special meeting. er the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revis...

8-KAgreement terminatedApr 138-K — Item 1.02: Agreement terminated · Item 2.03: Material debt obligation
8-KOfficer or director changeMar 98-K — Item 2.02: Earnings release · Item 5.02: Officer or director change
+ 10 other (2 10-Qs · 2 13Gs · 2 proxys · 1 425) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholdersglobenewswire.com·44d agoAre TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?gurufocus.com·51d ago$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)gurufocus.com·53d ago$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)prnewswire.com·53d agoBOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholdersbusinesswire.com·53d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ABCL$CAPR$ALLO$NWBO$TENX$AURA$SION$IBRX
Voices on X · top 4 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport